Lab
Coordinated Care Health Solutions, LLC
Coordinated Care Health Solutions, LLC was paid $5.79M by Medicaid between Jan 2018 and Dec 2024, across 110 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 25% of everything it billed.
33Billing provider infoCOORDINATED CARE HEALTH SOLUTIONS, LLC
OKLAHOMA CITY, OK 73114
OKLAHOMA CITY, OK 73114
33aNPI1871960195assigned 08/24/2015
33bProvider typeClinical Medical Laboratory
28Total paid$5.79M
24GClaims243,112
24DCodes billed110
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Oklahoma
Rank by total paid#6 of 46
Median peer was paid$248K
This provider vs. median23×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 90,029 | $1.48M | |
| 2019 | 78,248 | $1.73M | |
| 2020 | 35,187 | $1.10M | |
| 2021 | 22,452 | $877K | |
| 2022 | 8,330 | $361K | |
| 2023 | 4,690 | $139K | |
| 2024incomplete | 4,176 | $103K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 25% | 31,495 | 21,005 | $1.42M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 14% | 9,466 | 3,978 | $791K |
| 82542 | 8.4% | 12,656 | 11,229 | $486K | |
| 83789 | 6.5% | 9,324 | 8,914 | $378K | |
| 80050 | General health panel | 4.6% | 7,541 | 7,528 | $265K |
| 80164 | 2.7% | 12,257 | 10,872 | $155K | |
| 80173 | 2.6% | 11,235 | 9,887 | $153K | |
| 80156 | 2.6% | 11,222 | 9,879 | $152K | |
| 87799 | 2.5% | 1,269 | 1,229 | $144K | |
| 80175 | 2.4% | 11,237 | 9,889 | $138K | |
| 80201 | 2.1% | 11,183 | 9,841 | $124K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.9% | 1,247 | 760 | $112K |
98 more codes
| 80157 | 1.9% | 9,200 | $111K | |
| 80061 | Lipid panel | 1.9% | 9,472 | $111K |
| 80184 | 1.8% | 9,169 | $105K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.4% | 9,309 | $82K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,316 | $47K |
| 87652 | <1% | 1,270 | $47K | |
| 87481 | <1% | 1,270 | $40K | |
| 87641 | <1% | 1,269 | $40K | |
| 87653 | <1% | 1,270 | $40K | |
| 87500 | <1% | 1,270 | $40K | |
| 87640 | <1% | 1,266 | $39K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 5,834 | $38K |
| 80053 | Comprehensive metabolic panel | <1% | 3,792 | $34K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 627 | $32K |
| 80356 | <1% | 1,653 | $29K | |
| 80348 | <1% | 1,654 | $26K | |
| 84481 | <1% | 1,584 | $24K | |
| 80323 | <1% | 949 | $24K | |
| 80345 | <1% | 1,650 | $24K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 266 | $23K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 936 | $22K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 844 | $22K |
| 80358 | <1% | 1,651 | $22K | |
| 80324 | <1% | 1,651 | $20K | |
| 80365 | <1% | 1,649 | $20K | |
| 80353 | <1% | 1,653 | $19K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,517 | $19K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 873 | $18K |
| 80349 | <1% | 1,653 | $17K | |
| 80347 | <1% | 949 | $17K | |
| 80372 | <1% | 1,648 | $17K | |
| 80364 | <1% | 949 | $16K | |
| 80355 | <1% | 1,653 | $16K | |
| 84439 | <1% | 1,800 | $15K | |
| 80370 | <1% | 949 | $14K | |
| 80337 | <1% | 940 | $14K | |
| 80368 | <1% | 1,649 | $13K | |
| 80321 | <1% | 1,651 | $13K | |
| 80366 | <1% | 1,649 | $13K | |
| 80074 | <1% | 253 | $11K | |
| 80159 | <1% | 980 | $10K | |
| 80359 | <1% | 949 | $9K | |
| 80346 | <1% | 851 | $9K | |
| 80334 | <1% | 701 | $8K | |
| 80354 | <1% | 704 | $8K | |
| 80335 | <1% | 701 | $8K | |
| 80338 | <1% | 701 | $8K | |
| 86803 | <1% | 621 | $7K | |
| 80344 | <1% | 701 | $7K | |
| 80361 | <1% | 702 | $6K | |
| 80340 | <1% | 695 | $6K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 150 | $5K |
| 80178 | <1% | 768 | $5K | |
| 84403 | <1% | 185 | $5K | |
| 82670 | <1% | 170 | $5K | |
| 80373 | <1% | 700 | $5K | |
| 80357 | <1% | 704 | $4K | |
| 80369 | <1% | 700 | $4K | |
| 80360 | <1% | 702 | $4K | |
| 82607 | <1% | 303 | $4K | |
| 80367 | <1% | 700 | $3K | |
| 80377 | <1% | 697 | $3K | |
| 84146 | <1% | 291 | $3K | |
| 80363 | <1% | 450 | $3K | |
| 83001 | <1% | 169 | $3K | |
| 83992 | <1% | 729 | $3K | |
| 82570 | <1% | 732 | $3K | |
| 83002 | <1% | 156 | $3K | |
| 82533 | <1% | 147 | $2K | |
| 87900 | <1% | 21 | $2K | |
| 83986 | <1% | 1,279 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 59 | $2K |
| 81003 | <1% | 1,057 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 35 | $2K |
| 87529 | <1% | 30 | $2K | |
| 82746 | <1% | 127 | $2K | |
| 82977 | <1% | 261 | $2K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 59 | $2K |
| 80362 | <1% | 373 | $1K | |
| 83615 | <1% | 256 | $1K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 56 | $1K |
| 80299 | <1% | 31 | $1K | |
| 86703 | <1% | 109 | $987.04 | |
| 83540 | <1% | 148 | $925.33 | |
| 84100 | <1% | 202 | $891.88 | |
| 84550 | <1% | 185 | $775.10 | |
| 84466 | <1% | 56 | $594.55 | |
| 82248 | <1% | 93 | $488.22 | |
| 86780 | <1% | 40 | $457.64 | |
| 81001 | <1% | 83 | $236.48 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 880 | $192.88 |
| 82465 | <1% | 43 | $180.18 | |
| 83721 | <1% | 17 | $155.04 | |
| 86140 | <1% | 30 | $146.10 | |
| 82728 | <1% | 26 | $136.56 | |
| 86705 | <1% | 13 | $136.46 | |
| 83735 | <1% | 25 | $128.38 | |
| 87482 | <1% | 20 | $106.06 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHOGAN, HUNTER (OPERATIONS MANAGER)
| Provider | Location | Paid |
|---|---|---|
| Hunter's Specialty Pharmacy LLC | Oklahoma City, OK | $8.24 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.